AHA: Interatrial Shunt Effective at One Year in Heart Failure

Share this content:
AHA: Interatrial Shunt Effective at One Year in Heart Failure
AHA: Interatrial Shunt Effective at One Year in Heart Failure

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- Sustained clinical benefit has been observed in patients with heart failure with preserved left ventricular ejection fraction treated with an interatrial septal shunt device that allows shunting to reduce the left atrial pressure, according to a study published online Nov. 16 in Circulation: Heart Failure. The research was published to coincide with the annual meeting of the American Heart Association, held from Nov. 12 to 16 in New Orleans.

David Kaye, M.D., Ph.D., senior cardiologist at Alfred Hospital in Melbourne, Australia, and colleagues studied the device in 64 patients with left ventricular ejection fraction of 40 percent or higher, New York Heart Association class II to IV, and elevated pulmonary capillary wedge pressure (15 mm Hg or higher at rest or 25 mm Hg or higher during supine bicycle exercise).

The researchers found that survival at one year was 95 percent. The team noted sustained improvements in New York Heart Association class, quality of life, and six-minute walk distance. A small, stable reduction in left ventricular end-diastolic volume index, with a concomitant small stable increase in the right ventricular end-diastolic volume index was seen via echocardiography. A subset of patients also underwent invasive hemodynamic studies where a sustained reduction in the workload-corrected exercise pulmonary capillary wedge pressure was observed.

"These results provide evidence of safety and sustained clinical benefit in heart failure with preserved ejection fraction patients one year after interatrial septal shunt device implantation," the authors conclude. "Randomized, blinded studies are underway to confirm these observations."

The study was funded by Corvia Medical, which manufactures the interatrial shunt device.

Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »